You are now leaving GSK Malta Health Portal

You are about to leave a GSK Website. By clicking this link, you will be taken to an external website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on this site. If you do not wish to leave this website, click on “Go Back” below:

Continue

Go back

MLT_GIB/OTH/0007/17m
Date of preparation: March 2018

Synflorix allows flexible dosing

Synflorix provides flexibility of use by supporting different dosing schedules and co-administration with other commonly used paediatric vaccinations. 1

This includes a three-dose schedule, with or without a booster dose, or a two-dose schedule with a booster dose. 1

Synflorix is available in 0.5 ml single doses in prefilled syringes. 1

Please note: It is recommended that patients who receive a first dose of Synflorix complete the full vaccination course with Synflorix. 1

Synflorix can be given to pre-term infants born between 27 and 36 weeks’ gestation, as well as full-term infants 1

Method of administration

  • Synflorix is given by intramuscular injection 1
  • The preferred sites of injection are the thigh (anterolateral aspect) in infants or the upper arm (deltoid muscle) in young children 1
  • Synflorix should under no circumstances be administered intravascularly or intradermally 1
  • No data are available on subcutaneous administration of Synflorix 1

Before prescribing please consult the full SPC. 

 

Synflorix is a trade mark of the GlaxoSmithKline group of companies.